Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network. J Pediatric Infect Dis Soc 2024 Dec 30;13(12):633-638
Date
11/13/2024Pubmed ID
39513400Pubmed Central ID
PMC12476979DOI
10.1093/jpids/piae116Scopus ID
2-s2.0-85214460104 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined by clinical progression or worsening. Global treatment response at study completion was successful in 66 participants who transitioned to enteral therapy.
Author List
Bucayu RFT, Boge CLK, Yildirim I, Avilés-Robles M, Vora SB, Berman DM, Sharma TS, Sung L, Castagnola E, Palazzi DL, Danziger-Isakov L, Yin DE, Roilides E, Maron G, Tribble AC, Soler-Palacin P, López-Medina E, Romero J, Belani K, Arrieta AC, Carlesse F, Nolt D, Halasa N, Dulek D, Rajan S, Muller WJ, Ardura MI, Pong A, Gonzalez BE, Salvatore CM, Huppler AR, Aftandilian C, Abzug MJ, Chakrabarti A, Green M, Lutsar I, Knackstedt ED, Johnson SK, Steinbach WJ, Fisher BT, Wattier RLAuthor
Anna Huppler MD Associate Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Administration, IntravenousAdolescent
Antifungal Agents
Candidiasis, Invasive
Child
Child, Preschool
Cohort Studies
Female
Humans
Infant
Male
Treatment Outcome
Triazoles
